MX380108B - Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo - Google Patents

Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo

Info

Publication number
MX380108B
MX380108B MX2018010272A MX2018010272A MX380108B MX 380108 B MX380108 B MX 380108B MX 2018010272 A MX2018010272 A MX 2018010272A MX 2018010272 A MX2018010272 A MX 2018010272A MX 380108 B MX380108 B MX 380108B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pyrrolo
fused
membered heterocyclic
heterocyclic compound
Prior art date
Application number
MX2018010272A
Other languages
English (en)
Other versions
MX2018010272A (es
Inventor
Chenyang Wang
Tonghui Liu
Xinhua Zhang
Yun Lu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018010272A publication Critical patent/MX2018010272A/es
Publication of MX380108B publication Critical patent/MX380108B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende un compuesto heterocíclico de seis miembros fusionado con pirrolo o una sal farmacéuticamente aceptable del compuesto. Específicamente, la invención proporciona una composición farmacéutica que comprende 5-(2-dietilamino-etil)-2-(5-fluoro-2-oxo-1,2-dihidro-indol-3-iliden-metil)-3-5 metil-1,5,6,7-tetrahidro-pirrol o[3,2-c]piridín-4-ona o una sal farmacéuticamente aceptable de lo mismo, y al menos un agente de relleno hidrosoluble. La composición farmacéutica de la invención presenta una rápida disolución y buena estabilidad.
MX2018010272A 2016-03-01 2017-02-28 Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo MX380108B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610116472 2016-03-01
PCT/CN2017/075111 WO2017148359A1 (zh) 2016-03-01 2017-02-28 一种含有吡咯并六元杂环化合物或其可药用盐的药物组合物

Publications (2)

Publication Number Publication Date
MX2018010272A MX2018010272A (es) 2018-12-19
MX380108B true MX380108B (es) 2025-03-11

Family

ID=59743470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010272A MX380108B (es) 2016-03-01 2017-02-28 Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo

Country Status (17)

Country Link
US (1) US10973807B2 (es)
EP (1) EP3424500B1 (es)
JP (1) JP6948760B2 (es)
KR (1) KR20180112066A (es)
CN (1) CN107530331B (es)
AU (1) AU2017226420B2 (es)
BR (1) BR112018017155A2 (es)
CA (1) CA3015249A1 (es)
DK (1) DK3424500T3 (es)
ES (1) ES2907376T3 (es)
HU (1) HUE057830T2 (es)
MX (1) MX380108B (es)
PL (1) PL3424500T3 (es)
PT (1) PT3424500T (es)
RU (1) RU2737734C2 (es)
TW (1) TWI750152B (es)
WO (1) WO2017148359A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1973910T3 (pl) * 2006-01-27 2013-11-29 Shanghai hengrui pharmaceutical co ltd Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej
CN101007815B (zh) * 2006-01-27 2010-06-23 江苏恒瑞医药股份有限公司 吡咯并六元杂环化合物及其在医药上的用途
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
EP2113248A1 (en) * 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CN102266300B (zh) * 2011-07-14 2013-01-02 广东药学院 一种吉非替尼分散片及其制备方法和应用

Also Published As

Publication number Publication date
KR20180112066A (ko) 2018-10-11
HUE057830T2 (hu) 2022-06-28
AU2017226420B2 (en) 2022-07-07
TWI750152B (zh) 2021-12-21
EP3424500A1 (en) 2019-01-09
PT3424500T (pt) 2022-02-07
RU2737734C2 (ru) 2020-12-02
EP3424500B1 (en) 2022-01-26
EP3424500A4 (en) 2019-10-02
WO2017148359A1 (zh) 2017-09-08
MX2018010272A (es) 2018-12-19
CN107530331B (zh) 2018-12-04
AU2017226420A1 (en) 2018-08-30
CN107530331A (zh) 2018-01-02
ES2907376T3 (es) 2022-04-25
PL3424500T3 (pl) 2022-04-04
DK3424500T3 (da) 2022-02-21
JP6948760B2 (ja) 2021-10-13
RU2018132929A (ru) 2020-04-01
CA3015249A1 (en) 2017-09-08
US10973807B2 (en) 2021-04-13
BR112018017155A2 (pt) 2018-12-26
JP2019507151A (ja) 2019-03-14
RU2018132929A3 (es) 2020-05-13
TW201731508A (zh) 2017-09-16
US20190054073A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
GEP20217285B (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
IL257481B (en) Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof
EP3539963A4 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE
WO2013163244A8 (en) Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12016500170A1 (en) Formulation of syk inhibitors
GEAP201914546A (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
WO2015171526A3 (en) Tricyclic pyrazolopyridine compounds
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
PH12016502405A1 (en) 2-acylaminothiazole derivative or salt thereof
TN2016000491A1 (en) Carboxamide derivatives.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
HK1254636A1 (zh) 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
ZA201804663B (en) C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
SMT202200150T1 (it) Derivati penamici o loro sali, composizioni farmaceutiche e loro usi
BR112018017155A2 (pt) composição farmacêutica compreendendo composto heterocíclico de seis membros pirrolo-fundido
WO2016003827A3 (en) Fused cycloalkyl-pyrimidine compounds and uses thereof